ClinicalTrials.gg
CompletedNCT04867785Updated Jul 3, 2023Results posted

A Study of LY3437943 in Participants With Type 2 Diabetes

A Phase 2 interventional study of LY3437943 and Dulaglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 43 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
281
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing retatrutide in Diabetes Mellitus, Type 2 — none open to participants now, 3 under way, 3 of them phase 3. retatrutide · Diabetes Mellitus, Type 2.

Enrollment
6th of 10
281 · median 301
Started
2021
with 1 other
Phase 2
2 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
10 of 10
Eli Lilly and Company

Among the 10 studies testing retatrutide in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 2, and was the 3rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 10 studies testing retatrutide in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing retatrutide in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes (T2D)
  • Have an value at screening of ≥7.0% and ≤10.5% and treated with diet and exercise alone or with a stable dose of metformin (either immediate release or extended release, 1000 milligram (mg)/day and not more than the locally approved dose) for at least 3 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus (T1DM)
  • Have ketoacidosis
  • Have retinopathy, maculopathy
  • Have history of pancreatitis
  • Have obesity induced by other endocrine disorders
  • Have uncontrolled hypertension
  • Have acute or chronic hepatitis
  • Have chronic kidney disease
  • Have an abnormality for example, lupus or rheumatoid arthritis
  • Have an active or untreated
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
281 participants (actual)

Study arms

  • Experimental
    0.5 milligrams (mg) LY3437943

    Participants received 0.5 mg LY3437943 administered as SC (subcutaneous) injection once weekly (QW).

    Drug: LY3437943

  • Experimental
    4 mg LY3437943 (2 mg)

    Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.

    Drug: LY3437943

  • Experimental
    4 mg LY3437943 (4 mg)

    Participants received 4 mg LY3437943 administered as SC injection QW.

    Drug: LY3437943

  • Experimental
    8 mg LY3437943 (2 mg)

    Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.

    Drug: LY3437943

  • Experimental
    8 mg LY3437943 (4 mg)

    Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.

    Drug: LY3437943

  • Experimental
    12 mg LY3437943 (2 mg)

    Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as a SC injection QW.

    Drug: LY3437943

  • Active comparator
    1.5 mg Dulaglutide

    Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.

    Drug: Dulaglutide

  • Placebo comparator
    Placebo

    Participants received placebo administered as SC injection QW.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    Change in HbA1c (%) from baseline in LY3437943 relative to placebo. HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

    Time frame: Baseline, 24 Weeks

Secondary outcomes

  1. Change From Baseline in HbA1c

    Change in HbA1c (%) from baseline in LY3437943 relative to dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

    Time frame: Baseline, 24 Weeks

  2. Change From Baseline in HbA1c

    Change in HbA1c (%) from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline Body Mass Index (BMI) Group (\<30 kilograms/square meter (kg/m2), \>=30 kg/m2)\*Time + Baseline\*Time.

    Time frame: Baseline, 36 Weeks

  3. Percentage of Participants Reaching HbA1c <7.0%

    Percentage of participants reaching HbA1c \<7.0% in LY3437943 relative to placebo and dulaglutide. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<30 kg/m2, ≥30 kg/m2\] as fixed effects, and baseline HbA1c value as a covariate.

    Time frame: Week 24

  4. Percentage of Participant Reaching HbA1c <7.0%

    Percentage of participants reaching HbA1c \<7.0% in LY3437943 relative to placebo and dulaglutide. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<30 kg/m2, ≥30 kg/m2\] as fixed effects, and baseline HbA1c value as a covariate.

    Time frame: Week 36

  5. Change From Baseline in Fasting Blood Glucose (FBG)

    Change in FBG from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

    Time frame: Baseline, 24 Weeks

  6. Change From Baseline in Fasting Blood Glucose (FBG)

    Change in FBG from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline BMI Group (\<30kg/m2, \>=30kg/m2)\*Time + Baseline\*Time.

    Time frame: Baseline, 36 Weeks

  7. Change From Baseline in Body Weight

    Change in body weight from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

    Time frame: Baseline, 24 Weeks

  8. Change From Baseline in Body Weight

    Change in body weight from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline BMI Group (\<30kg/m2, \>=30kg/m2)\*Time + Baseline\*Time.

    Time frame: Baseline, 36 Weeks

  9. Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943

    The average steady-state plasma concentration of LY3437943 was evaluated using sparse sampling methodology/Population PK (PopPK) modeling.

    Time frame: Predose: Week 0, 1, 4, 12, 24, 30; Postdose: Week 2, 8, 16, 20, 36

07

Results

Posted Jul 3, 2023

Participant flow

Participant flow — Overall Study
MilestonePlacebo1.5 Milligrams (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Started4546472324262446
Received at least 1 dose of study drug4546472324262446
Completed3440411921252235
Not completed1166431211
Withdrew: Adverse event10100002
Withdrew: Lost to follow-up44320101
Withdrew: Withdrawal by subject62212025
Withdrew: Physician decision00000001
Withdrew: Inadvertent enrollment00011001
Withdrew: Eligibility criteria not met00000001

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c)

Change in HbA1c (%) from baseline in LY3437943 relative to placebo. HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

Time frame:
Baseline, 24 Weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
percentage of HbA1cPlacebo1.5 mg Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Change From Baseline in Hemoglobin A1c (HbA1c)-0.05 ± 0.21-1.41 ± 0.12-0.43 ± 0.20-1.39 ± 0.14-1.30 ± 0.22-1.99 ± 0.15-1.88 ± 0.21-2.01 ± 0.11
Statistical analysis
  • Placebo vs 0.5 mg LY3437943 · Mixed Models Analysis · p = 0.188 · Least squares (ls) mean difference: -0.38 · 95% CI -0.94 to 0.18
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.34 · 95% CI -1.84 to -0.85
  • Placebo vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.25 · 95% CI -1.85 to -0.65
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.94 · 95% CI -2.44 to -1.43
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.83 · 95% CI -2.42 to -1.24
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.96 · 95% CI -2.43 to -1.50
SecondaryChange From Baseline in HbA1c

Change in HbA1c (%) from baseline in LY3437943 relative to dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

Time frame:
Baseline, 24 Weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c
percentage of HbA1cPlacebo1.5 Milligram (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Change From Baseline in HbA1c-0.05 ± 0.21-1.41 ± 0.12-0.43 ± 0.20-1.39 ± 0.14-1.30 ± 0.22-1.99 ± 0.15-1.88 ± 0.21-2.01 ± 0.11
Statistical analysis
  • 1.5 Milligram (mg) Dulaglutide vs 0.5 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.98 · 95% CI 0.52 to 1.43
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.935 · Lsmean difference: 0.01 · 95% CI -0.34 to 0.37
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.668 · Lsmean difference: 0.11 · 95% CI -0.39 to 0.60
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.002 · Lsmean difference: -0.58 · 95% CI -0.95 to -0.21
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.056 · Lsmean difference: -0.47 · 95% CI -0.95 to 0.01
  • 1.5 Milligram (mg) Dulaglutide vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -0.61 · 95% CI -0.93 to -0.29
SecondaryChange From Baseline in HbA1c

Change in HbA1c (%) from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline Body Mass Index (BMI) Group (\<30 kilograms/square meter (kg/m2), \>=30 kg/m2)\*Time + Baseline\*Time.

Time frame:
Baseline, 36 Weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c
percentage of HbA1cPlacebo1.5 Milligram (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Change From Baseline in HbA1c-0.30 ± 0.24-1.36 ± 0.13-0.54 ± 0.20-1.30 ± 0.20-1.50 ± 0.19-2.13 ± 0.17-1.93 ± 0.22-2.16 ± 0.13
Statistical analysis
  • Placebo vs 0.5 mg LY3437943 · Mixed Models Analysis · p = 0.448 · Lsmean difference: -0.24 · 95% CI -0.85 to 0.38
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.001 · Lsmean difference: -0.99 · 95% CI -1.60 to -0.38
  • Placebo vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.20 · 95% CI -1.80 to -0.59
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.83 · 95% CI -2.41 to -1.24
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.63 · 95% CI -2.27 to -0.99
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -1.85 · 95% CI -2.39 to -1.31
  • 1.5 Milligram (mg) Dulaglutide vs 0.5 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.82 · 95% CI 0.35 to 1.29
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.796 · Lsmean difference: 0.06 · 95% CI -0.41 to 0.53
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.548 · Lsmean difference: -0.14 · 95% CI -0.61 to 0.32
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -0.77 · 95% CI -1.19 to -0.36
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.025 · Lsmean difference: -0.57 · 95% CI -1.08 to -0.07
  • 1.5 Milligram (mg) Dulaglutide vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -0.80 · 95% CI -1.16 to -0.44
SecondaryPercentage of Participants Reaching HbA1c <7.0%

Percentage of participants reaching HbA1c \<7.0% in LY3437943 relative to placebo and dulaglutide. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<30 kg/m2, ≥30 kg/m2\] as fixed effects, and baseline HbA1c value as a covariate.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching HbA1c <7.0%
percentage of participantsPlacebo1.5 Milligram (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Percentage of Participants Reaching HbA1c <7.0%1852325366887886
Statistical analysis
  • Placebo vs 0.5 mg LY3437943 · Regression, Logistic · p = 0.121 · Risk difference (rd): 0.14 · 95% CI -0.04 to 0.32
  • Placebo vs 4 mg LY3437943 (2 mg) · Regression, Logistic · p = 0.002 · Risk difference (rd): 0.36 · 95% CI 0.13 to 0.59
  • Placebo vs 4 mg LY3437943 (4 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 0.48 · 95% CI 0.28 to 0.68
  • Placebo vs 8 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 0.70 · 95% CI 0.53 to 0.87
  • Placebo vs 8 mg LY3437943 (4 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 0.60 · 95% CI 0.39 to 0.82
  • Placebo vs 12 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 0.68 · 95% CI 0.51 to 0.85
  • 1.5 Milligram (mg) Dulaglutide vs 0.5 mg LY3437943 · Regression, Logistic · p = 0.030 · Risk difference (rd): -0.21 · 95% CI -0.39 to -0.02
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (2 mg) · Regression, Logistic · p = 0.938 · Risk difference (rd): 0.01 · 95% CI -0.22 to 0.24
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (4 mg) · Regression, Logistic · p = 0.209 · Risk difference (rd): 0.13 · 95% CI -0.07 to 0.33
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 0.35 · 95% CI 0.18 to 0.53
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (4 mg) · Regression, Logistic · p = 0.024 · Risk difference (rd): 0.26 · 95% CI 0.03 to 0.48
  • 1.5 Milligram (mg) Dulaglutide vs 12 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 0.33 · 95% CI 0.16 to 0.51
SecondaryPercentage of Participant Reaching HbA1c <7.0%

Percentage of participants reaching HbA1c \<7.0% in LY3437943 relative to placebo and dulaglutide. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<30 kg/m2, ≥30 kg/m2\] as fixed effects, and baseline HbA1c value as a covariate.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participant Reaching HbA1c <7.0%
percentage of participantsPlacebo1.5 Milligram (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Percentage of Participant Reaching HbA1c <7.0%2260376159827880
Statistical analysis
  • Placebo vs 0.5 mg LY3437943 · Regression, Logistic · p = 0.169 · Risk difference (rd): 0.14 · 95% CI -0.06 to 0.35
  • Placebo vs 4 mg LY3437943 (2 mg) · Regression, Logistic · p = 0.001 · Risk difference (rd): 0.39 · 95% CI 0.15 to 0.63
  • Placebo vs 4 mg LY3437943 (4 mg) · Regression, Logistic · p = 0.002 · Risk difference (rd): 0.37 · 95% CI 0.14 to 0.60
  • Placebo vs 8 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 0.59 · 95% CI 0.39 to 0.79
  • Placebo vs 8 mg LY3437943 (4 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 0.56 · 95% CI 0.34 to 0.78
  • Placebo vs 12 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 0.57 · 95% CI 0.38 to 0.76
  • 1.5 Milligram (mg) Dulaglutide vs 0.5 mg LY3437943 · Regression, Logistic · p = 0.029 · Risk difference (rd): -0.23 · 95% CI -0.44 to -0.02
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (2 mg) · Regression, Logistic · p = 0.898 · Risk difference (rd): 0.02 · 95% CI -0.22 to 0.25
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (4 mg) · Regression, Logistic · p = 0.968 · Risk difference (rd): 0.00 · 95% CI -0.24 to 0.23
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (2 mg) · Regression, Logistic · p = 0.033 · Risk difference (rd): 0.22 · 95% CI 0.02 to 0.42
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (4 mg) · Regression, Logistic · p = 0.099 · Risk difference (rd): 0.19 · 95% CI -0.04 to 0.41
  • 1.5 Milligram (mg) Dulaglutide vs 12 mg LY3437943 (2 mg) · Regression, Logistic · p = 0.044 · Risk difference (rd): 0.20 · 95% CI 0.01 to 0.39
SecondaryChange From Baseline in Fasting Blood Glucose (FBG)

Change in FBG from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

Time frame:
Baseline, 24 Weeks
Reported as:
Least squares mean · milligrams/deciliter (mg/dL)
Change From Baseline in Fasting Blood Glucose (FBG)
milligrams/deciliter (mg/dL)Placebo1.5 Milligram (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Change From Baseline in Fasting Blood Glucose (FBG)-10.59 ± 5.98-46.26 ± 4.35-12.71 ± 6.95-30.19 ± 12.65-43.89 ± 8.42-66.09 ± 3.70-39.80 ± 10.79-65.20 ± 4.38
Statistical analysis
  • Placebo vs 0.5 mg LY3437943 · Mixed Models Analysis · p = 0.823 · Lsmean difference: -2.12 · 95% CI -20.73 to 16.48
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.165 · Lsmean difference: -19.60 · 95% CI -47.29 to 8.10
  • Placebo vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.001 · Lsmean difference: -33.30 · 95% CI -53.56 to -13.04
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -55.50 · 95% CI -69.77 to -41.22
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.015 · Lsmean difference: -29.22 · 95% CI -52.84 to -5.59
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -54.61 · 95% CI -69.63 to -39.59
  • 1.5 Milligram (mg) Dulaglutide vs 0.5 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Lsmean difference: 33.54 · 95% CI 18.26 to 48.82
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.231 · Lsmean difference: 16.07 · 95% CI -10.25 to 42.39
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.804 · Lsmean difference: 2.37 · 95% CI -16.28 to 21.01
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -19.83 · 95% CI -31.01 to -8.65
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.586 · Lsmean difference: 6.45 · 95% CI -16.75 to 29.65
  • 1.5 Milligram (mg) Dulaglutide vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.002 · Lsmean difference: -18.94 · 95% CI -30.93 to -6.96
SecondaryChange From Baseline in Fasting Blood Glucose (FBG)

Change in FBG from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline BMI Group (\<30kg/m2, \>=30kg/m2)\*Time + Baseline\*Time.

Time frame:
Baseline, 36 Weeks
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Blood Glucose (FBG)
mg/dLPlacebo1.5 Milligram (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Change From Baseline in Fasting Blood Glucose (FBG)-17.26 ± 10.87-27.53 ± 9.07-17.51 ± 5.59-21.46 ± 12.54-38.72 ± 10.81-69.10 ± 4.68-41.20 ± 14.43-67.84 ± 4.79
Statistical analysis
  • Placebo vs 0.5 mg LY3437943 · Mixed Models Analysis · p = 0.984 · Lsmean difference: -0.25 · 95% CI -24.57 to 24.07
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.804 · Lsmean difference: -4.20 · 95% CI -37.44 to 29.03
  • Placebo vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.167 · Lsmean difference: -21.47 · 95% CI -51.91 to 8.98
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -51.84 · 95% CI -76.09 to -27.59
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.168 · Lsmean difference: -23.94 · 95% CI -57.94 to 10.06
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -50.58 · 95% CI -74.94 to -26.22
  • 1.5 Milligram (mg) Dulaglutide vs 0.5 mg LY3437943 · Mixed Models Analysis · p = 0.362 · Lsmean difference: 10.02 · 95% CI -11.55 to 31.60
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.696 · Lsmean difference: 6.07 · 95% CI -24.34 to 36.48
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.436 · Lsmean difference: -11.19 · 95% CI -39.38 to 16.99
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -41.57 · 95% CI -62.89 to -20.25
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = 0.418 · Lsmean difference: -13.67 · 95% CI -46.75 to 19.42
  • 1.5 Milligram (mg) Dulaglutide vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -40.31 · 95% CI -60.77 to -19.85
SecondaryChange From Baseline in Body Weight

Change in body weight from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.

Time frame:
Baseline, 24 Weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight
kilograms (kg)Placebo1.5 Milligram (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Change From Baseline in Body Weight-1.86 ± 0.66-1.16 ± 0.63-2.35 ± 0.48-6.27 ± 0.94-8.64 ± 1.23-11.99 ± 0.84-13.91 ± 1.38-12.84 ± 0.93
Statistical analysis
  • Placebo vs 0.5 mg LY3437943 · Mixed Models Analysis · p = 0.540 · Lsmean difference: -0.49 · 95% CI -2.07 to 1.08
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -4.41 · 95% CI -6.69 to -2.13
  • Placebo vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -6.78 · 95% CI -9.47 to -4.09
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -10.13 · 95% CI -12.24 to -8.03
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -12.06 · 95% CI -15.06 to -9.06
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -10.99 · 95% CI -13.24 to -8.73
  • 1.5 Milligram (mg) Dulaglutide vs 0.5 mg LY3437943 · Mixed Models Analysis · p = 0.135 · Lsmean difference: -1.19 · 95% CI -2.75 to 0.37
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -5.11 · 95% CI -7.36 to -2.86
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -7.48 · 95% CI -10.19 to -4.77
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -10.83 · 95% CI -12.89 to -8.77
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -12.76 · 95% CI -15.74 to -9.77
  • 1.5 Milligram (mg) Dulaglutide vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -11.69 · 95% CI -13.90 to -9.47
SecondaryChange From Baseline in Body Weight

Change in body weight from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline BMI Group (\<30kg/m2, \>=30kg/m2)\*Time + Baseline\*Time.

Time frame:
Baseline, 36 Weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight
kilograms (kg)Placebo1.5 Milligram (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Change From Baseline in Body Weight-3.28 ± 0.92-1.97 ± 0.87-3.31 ± 0.62-7.28 ± 1.39-10.37 ± 1.49-16.48 ± 1.55-16.12 ± 1.63-17.18 ± 1.32
Statistical analysis
  • Placebo vs 0.5 mg LY3437943 · Mixed Models Analysis · p = 0.979 · Lsmean difference: -0.03 · 95% CI -2.18 to 2.12
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.018 · Lsmean difference: -4.00 · 95% CI -7.32 to -0.68
  • Placebo vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -7.09 · 95% CI -10.46 to -3.71
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -13.20 · 95% CI -16.74 to -9.66
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -12.84 · 95% CI -16.50 to -9.18
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -13.91 · 95% CI -17.10 to -10.71
  • 1.5 Milligram (mg) Dulaglutide vs 0.5 mg LY3437943 · Mixed Models Analysis · p = 0.213 · Lsmean difference: -1.34 · 95% CI -3.45 to 0.77
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = 0.002 · Lsmean difference: -5.31 · 95% CI -8.66 to -1.97
  • 1.5 Milligram (mg) Dulaglutide vs 4 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -8.40 · 95% CI -11.76 to -5.04
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -14.51 · 95% CI -18.00 to -11.01
  • 1.5 Milligram (mg) Dulaglutide vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -14.15 · 95% CI -17.77 to -10.54
  • 1.5 Milligram (mg) Dulaglutide vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Lsmean difference: -15.22 · 95% CI -18.36 to -12.07
SecondaryPopulation PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943

The average steady-state plasma concentration of LY3437943 was evaluated using sparse sampling methodology/Population PK (PopPK) modeling.

Time frame:
Predose: Week 0, 1, 4, 12, 24, 30; Postdose: Week 2, 8, 16, 20, 36
Reported as:
Number · nanograms/milliliter (ng/mL)
Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943
nanograms/milliliter (ng/mL)0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY343794362.8466551110011401620

Adverse events

Collected over Baseline Through Study Completion (Up to 280 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/45 (0%)3/45 (6.7%)15/45 (33.3%)
1.5 Milligram (mg) Dulaglutide0/46 (0%)1/46 (2.2%)24/46 (52.2%)
0.5 mg LY34379430/47 (0%)3/47 (6.4%)15/47 (31.9%)
4 mg LY3437943 (2 mg)0/23 (0%)1/23 (4.3%)9/23 (39.1%)
4 mg LY3437943 (4 mg)0/24 (0%)2/24 (8.3%)17/24 (70.8%)
8 mg LY3437943 (2 mg)0/26 (0%)2/26 (7.7%)16/26 (61.5%)
8 mg LY3437943 (4 mg)0/24 (0%)1/24 (4.2%)15/24 (62.5%)
12 mg LY3437943 (2 mg)0/46 (0%)2/46 (4.3%)25/46 (54.3%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlacebo1.5 Milligram (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Transurethral prostatectomySurgical and medical procedures1/220/130/240/150/120/100/90/20
Cardiac failure congestiveCardiac disorders0/450/461/471/230/240/260/240/46
Cholecystitis chronicHepatobiliary disorders0/450/460/470/230/240/261/240/46
Osteomyelitis acuteInfections and infestations0/450/460/470/231/240/260/240/46
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/450/460/470/231/240/260/240/46
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/450/460/470/231/240/260/240/46
Atrial fibrillationCardiac disorders0/450/460/470/230/241/260/240/46
Pancreatitis acuteGastrointestinal disorders0/450/461/470/230/241/260/240/46
Abdominal herniaGastrointestinal disorders1/450/460/470/230/240/260/240/46
CellulitisInfections and infestations1/450/460/470/230/240/260/241/46
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlacebo1.5 Milligram (mg) Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
NauseaGastrointestinal disorders2/458/462/472/236/247/2610/249/46
DiarrhoeaGastrointestinal disorders2/454/461/472/236/245/267/247/46
Decreased appetiteMetabolism and nutrition disorders0/456/462/471/235/245/264/249/46
ConstipationGastrointestinal disorders1/453/463/472/234/243/262/245/46
VomitingGastrointestinal disorders1/454/461/471/230/242/264/245/46
Covid-19Infections and infestations3/454/465/473/231/241/261/242/46
FlatulenceGastrointestinal disorders0/451/460/470/231/240/263/240/46
FatigueGeneral disorders0/450/461/471/232/241/263/243/46
Urinary tract infectionInfections and infestations2/451/460/470/231/241/263/245/46
DizzinessNervous system disorders1/451/460/472/232/241/263/242/46

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Placebo1.5 mg Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)Total
Mean57.56 ± 10.8354.94 ± 10.4557.21 ± 9.6957.70 ± 8.1457.58 ± 10.0057.00 ± 7.3753.83 ± 9.0354.37 ± 9.7256.19 ± 9.68
Sex: Female, Male
Sex: Female, Male(Participants)Placebo1.5 mg Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)Total
Female233323812161526156
Male221324151210920125
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo1.5 mg Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)Total
Hispanic or Latino21202791312920131
Not Hispanic or Latino2326201410141526148
Unknown or Not Reported100010002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo1.5 mg Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)Total
American Indian or Alaska Native000000022
Asian310200028
Native Hawaiian or Other Pacific Islander000000000
Black or African American5961234333
White3636402022232038235
More than one race101000002
Unknown or Not Reported000000011
Region of Enrollment
Region of Enrollment(participants)Placebo1.5 mg Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)Total
United States4546472324262446281
Percentage of Hemoglobin A1c (HbA1c) at Baseline
Percentage of Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c)Placebo1.5 mg Dulaglutide0.5 mg LY34379434 mg LY3437943 (2 mg)4 mg LY3437943 (4 mg)8 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)Total
Mean8.39 ± 1.1398.22 ± 0.9198.35 ± 1.1728.07 ± 0.8708.20 ± 1.2078.34 ± 1.1208.20 ± 1.2618.28 ± 1.0668.27 ± 1.086
08

Study locations

43 sites
  • Syed Research Consultants Llc
    Sheffield, Alabama 35660, United States
  • San Fernando Valley Health Institute
    Canoga Park, California 91304, United States
  • Valley Endocrine, Fresno
    Fresno, California 93720, United States
  • National Research Institute - Huntington Park
    Huntington Park, California 90255, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • National Research Institute - Panorama City
    Panorama City, California 91402, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • National Research Institute (NRI) - Santa Ana
    Santa Ana, California 92704, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • South Florida Clinical Research Institute
    Margate, Florida 33063, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Encore Medical Research - Weston
    Weston, Florida 33331, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Humphreys Diabetes Center
    Boise, Idaho 83702, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Elite Clinical Trials
    Rexburg, Idaho 83440, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Cotton O'Neil Clinic
    Topeka, Kansas 66606, United States
  • Centennial Medical Group
    Elkridge, Maryland 21075, United States
  • MediSync Clinical Research
    Petal, Mississippi 39465, United States
  • Clinvest Research LLC
    Springfield, Missouri 65810, United States
  • Logan Health Research
    Kalispell, Montana 59901, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • Intend Research, LLC
    Norman, Oklahoma 73069, United States
  • Heritage Valley Medical Group, Inc.
    Beaver, Pennsylvania 15009, United States
  • Preferred Primary Care Physicians
    Pittsburgh, Pennsylvania 15236, United States
  • Frontier Clinical Research, LLC
    Smithfield, Pennsylvania 15478, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • The Research Center of The Upstate
    Greenville, South Carolina 29607, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Diabetes and Thyroid Center of Fort Worth
    Fort Worth, Texas 76132, United States
  • Endocrine Ips, Pllc
    Houston, Texas 77079, United States
  • Laila A Hassan, MD, PA
    Houston, Texas 77089, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • North Hills Family Medicine/North Hills Medical Research
    North Richland Hills, Texas 76180, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Universal Research Group
    Tacoma, Washington 98405, United States
  • The Vancouver Clinic
    Vancouver, Washington 98664, United States
  • Advanced Clinical Research, LLC
    Bayamon, 00961, Puerto Rico
  • Manati Center for Clinical Research
    Manati, 674, Puerto Rico
  • Latin Clinical Trial Center
    San Juan, 909, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jul 2022, 13 months.

Results were first posted in Jul 2023, 11 months after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 13 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
Apr 30, 2021
StartActual
May 13, 2021
Primary completionActual
Jul 8, 2022
CompletionActual
Oct 27, 2022
Results first posted
Jul 3, 2023
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04867785
Responsible party
Sponsor
First posted
Apr 30, 2021
Start date
May 13, 2021
Primary completion
Jul 8, 2022
Completion
Oct 27, 2022
Results posted
Jul 3, 2023
Last update
Jul 3, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion